Monday, May 20, 2019

Daily Wrapup - Monday May 20th

Today is the inaugural day of a new format.  Let me know how you like it:

AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
AbbVie Press Release
-More bad news from the world of ADC.

Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
Business Wire
-Exelixis is announcing that they are licensing the ICON-1 asset from Iconic Therapeutics  targeting Tissue Factor in cancer cells.

SUN-174 Severe Insulin Resistance and Diabetic Ketoacidosis after Brentuximab Vendotin and Cyclosporin Treatment
Journal of the Endocrin Society
-Brentuximab vedotin induces full diabetic ketoacidosis episode in 23 year old patient.  Take a second to realize how potent these molecules that we are dealing with actually are.

As Daiichi Sankyo-partnered breast cancer drug marches toward finish line, AstraZeneca brings in Canadian scientist Sunil Verma to rev up R&D
Endpoints News
- A massive $7 billion licensing agreement was only the start of a shake-up at AZ.  Add in the removal of MedImmune as a separate entity and now a shakeup at the executive level.  This is a pretty big reckoning for the guys and gals over there.

'Cornucopia' of biopharma innovation blurs drug launch forecasts, analyst laments
- New technologies mean new cures, but the onslaught of completely new therapies also means increased uncertainty, and that results in higher prices.  Pretty interesting stuff.

- - - [Main]

No comments:

Post a Comment